Literature DB >> 28768149

The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer's disease.

Kahli Zeitlow1, Lefko Charlambous2, Isaac Ng3, Sonal Gagrani3, Mirta Mihovilovic4, Shuhong Luo5, Daniel L Rock5, Ann Saunders6, Allen D Roses7, W Kirby Gottschalk8.   

Abstract

A variable-length poly-T variant in intron 6 of the TOMM40 gene, rs10524523, is associated with risk and age-of-onset of sporadic (late-onset) Alzheimer's disease. In Caucasians, the three predominant alleles at this locus are Short (S), Long (L) or Very long (VL). On an APOE ε3/3 background, the S/VL and VL/VL genotypes are more protective than S/S. The '523 poly-T has regulatory properties, in that the VL poly-T results in higher expression than the S poly-T in luciferase expression systems. The aim of the current work was to identify effects on cellular bioenergetics of increased TOM40 protein expression. MitoTracker Green fluorescence and autophagic vesicle staining was the same in control and over-expressing cells, but TOM40 over-expression was associated with increased expression of TOM20, a preprotein receptor of the TOM complex, the mitochondrial chaperone HSPA9, and PDHE1a, and increased activities of the oxidative phosphorylation complexes I and IV and of the TCA member α-ketoglutaric acid dehydrogenase. Consistent with the complex I findings, respiration was more sensitive to inhibition by rotenone in control cells than in the TOM40 over-expressing cells. In the absence of inhibitors, total cellular ATP, the mitochondrial membrane potential, and respiration were elevated in the over-expressing cells. Spare respiratory capacity was greater in the TOM40 over-expressing cells than in the controls. TOM40 over-expression blocked Ab-elicited decreases in the mitochondrial membrane potential, cellular ATP levels, and cellular viability in the control cells. These data suggest elevated expression of TOM40 may be protective of mitochondrial function.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's; Energetics; Mitochondria; Neurodegeneration; TOM; TOMM40

Mesh:

Substances:

Year:  2017        PMID: 28768149      PMCID: PMC5659897          DOI: 10.1016/j.bbadis.2017.07.031

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  18 in total

Review 1.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

Review 2.  Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention.

Authors:  Yunhua Peng; Peipei Gao; Le Shi; Lei Chen; Jiankang Liu; Jiangang Long
Journal:  Antioxid Redox Signal       Date:  2020-03-16       Impact factor: 8.401

3.  Structural basis of Tom20 and Tom22 cytosolic domains as the human TOM complex receptors.

Authors:  Jiayue Su; Desheng Liu; Fan Yang; Mei-Qing Zuo; Chang Li; Meng-Qiu Dong; Shan Sun; Sen-Fang Sui
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-22       Impact factor: 12.779

4.  Hidden heterogeneity in Alzheimer's disease: Insights from genetic association studies and other analyses.

Authors:  Anatoliy I Yashin; Fang Fang; Mikhail Kovtun; Deqing Wu; Matt Duan; Konstantin Arbeev; Igor Akushevich; Alexander Kulminski; Irina Culminskaya; Ilya Zhbannikov; Arseniy Yashkin; Eric Stallard; Svetlana Ukraintseva
Journal:  Exp Gerontol       Date:  2017-10-26       Impact factor: 4.032

5.  An Aging-Related Single-Nucleotide Polymorphism is Associated With Altered Clinical Outcomes and Distinct Inflammatory Profiles in Aged Blunt Trauma Patients.

Authors:  Ashley J Lamparello; Rami A Namas; Lukas Schimunek; Maria Cohen; Fayten El-Dehaibi; Jinling Yin; Derek Barclay; Ruben Zamora; Timothy R Billiar; Yoram Vodovotz
Journal:  Shock       Date:  2020-02       Impact factor: 3.533

6.  Therapeutic considerations for APOE and TOMM40 in Alzheimers disease: A tribute to Allen Roses MD.

Authors:  Marwan Noel Sabbagh; Evans Pope; Laura Cordes; Jiong Shi; Boris DeCourt
Journal:  Expert Opin Investig Drugs       Date:  2020-12-02       Impact factor: 6.498

Review 7.  Healthspan pathway maps in C. elegans and humans highlight transcription, proliferation/biosynthesis and lipids.

Authors:  Steffen Möller; Nadine Saul; Alan A Cohen; Rüdiger Köhling; Sina Sender; Christian Junghanss; Francesca Cirulli; Alessandra Berry; Peter Antal; Priit Adler; Jaak Vilo; Michele Boiani; Ludger Jansen; Dirk Repsilber; Hans Jörgen Grabe; Stephan Struckmann; Israel Barrantes; Mohamed Hamed; Brecht Wouters; Liliane Schoofs; Walter Luyten; Georg Fuellen
Journal:  Aging (Albany NY)       Date:  2020-07-07       Impact factor: 5.682

8.  Computer-Aided Multi-Target Management of Emergent Alzheimer's Disease.

Authors:  Hyunjo Kim; Hyunwook Han
Journal:  Bioinformation       Date:  2018-05-05

9.  Biothiols and oxidative stress markers and polymorphisms of TOMM40 and APOC1 genes in Alzheimer's disease patients.

Authors:  Michal Prendecki; Jolanta Florczak-Wyspianska; Marta Kowalska; Jan Ilkowski; Teresa Grzelak; Katarzyna Bialas; Malgorzata Wiszniewska; Wojciech Kozubski; Jolanta Dorszewska
Journal:  Oncotarget       Date:  2018-10-16

10.  TOMM40 '523' poly-T repeat length is a determinant of longitudinal cognitive decline in Parkinson's disease.

Authors:  Megan C Bakeberg; Anastazja M Gorecki; Abigail L Pfaff; Madison E Hoes; Sulev Kõks; P Anthony Akkari; Frank L Mastaglia; Ryan S Anderton
Journal:  NPJ Parkinsons Dis       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.